Welcome to our dedicated page for Revance Therapeutics news (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeutics stock.
Revance Therapeutics, Inc. (symbol: RVNC) is a specialty biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative botulinum toxin products for various aesthetic and therapeutic uses. Leveraging its proprietary portfolio of botulinum toxin compounds and the patented TransMTS® peptide delivery system, Revance aims to address unmet needs in the $3 billion neurotoxin market.
The company’s unique TransMTS technology allows for the delivery of botulinum toxin A in two distinctive formulations: a needle-free topical form and an injectable form that targets the site of injection for a potentially longer-lasting effect. Revance is actively pursuing clinical development for two main product candidates: Topical RT001 and Injectable RT002. RT001 is a topical gel with the potential to become the first commercially available non-injectable botulinum toxin dose form.
Additionally, Revance has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Their primary products, DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics, are central to their aesthetic and therapeutic offerings.
Revance operates through two main business segments: Product and Service. The Products segment, which generates the majority of the company’s revenue, focuses on the research and development of aesthetic and therapeutic products. Recent achievements and ongoing developments reflect the company’s commitment to advancing the field of neuromodulation.
Revance Therapeutics, Inc. (Nasdaq: RVNC) reported a first quarter 2021 revenue of $13.3 million, a significant increase from $0.1 million in Q1 2020, driven primarily by the RHA® Collection of dermal fillers. However, the company faced a net loss of $71.6 million. SG&A expenses rose to $49.0 million, while R&D expenses decreased to $27.3 million. Cash equivalents stood at $386.8 million, and the company raised $21.7 million from its ATM program. The FDA's review of DaxibotulinumtoxinA for Injection remains pending due to inspection scheduling delays.
Revance Therapeutics, Inc. (Nasdaq: RVNC) will release its first quarter 2021 financial results on May 10, 2021, after market close. A conference call and live webcast discussing these results will take place at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Revance is known for its neuromodulator product, DaxibotulinumtoxinA for Injection, which has completed Phase 3 trials and is awaiting U.S. regulatory approval. The company also holds exclusive U.S. distribution rights for RHA® Collection dermal fillers and is developing a biosimilar to BOTOX® in partnership with Viatris.
Revance Therapeutics (Nasdaq: RVNC) announced a presentation at The American Society for Aesthetic Plastic Surgery Aesthetic Meeting 2021, highlighting data from the Phase 3 SAKURA clinical program. This analysis demonstrated the efficacy, safety, and duration of DaxibotulinumtoxinA for Injection in treating glabellar lines across various female age groups. With over 3,000 subjects, the data confirmed a median time to loss of none or mild symptoms lasting at least 24 weeks. Revance is seeking FDA approval for this treatment, aiming to transform patient experiences in the aesthetic and therapeutic markets.
Revance Therapeutics (Nasdaq: RVNC) has announced the initiation of Phase 3 trials for DaxibotulinumtoxinA in China, aimed at treating glabellar lines and cervical dystonia. The first patients were dosed in April 2023. The Chinese market for neuromodulators is rapidly growing, projected to expand from $318 million in 2021 to $762 million by 2027. Revance has a licensing agreement with Fosun Pharma, which includes potential milestone payments of $230 million and royalties based on future sales.
Revance Therapeutics has announced it will present four ePoster abstracts at the AAD VMX meeting from April 23-25, 2021. These presentations include new data from the SAKURA Phase 3 program for DaxibotulinumtoxinA for Injection, highlighting its effectiveness in eliminating glabellar lines. The abstracts also feature subgroup analysis of efficacy among adult females and the impact of hyaluronic acid filler manufacturing on HA chain degradation. Attendees can access sessions on-demand until July 12, 2021, via the AAD website.
Revance Therapeutics, Inc. (Nasdaq: RVNC) will participate in the 20th Annual Needham Virtual Healthcare Conference from April 12-15. CEO Mark Foley is scheduled for a fireside chat on April 13 at 7:15 a.m. PT / 10:15 a.m. ET. Interested parties can access the live audio webcast via the Investor Relations section on www.revance.com. The conference will feature the company's innovative products, including DaxibotulinumtoxinA for Injection, a next-generation neuromodulator targeting various aesthetic and therapeutic applications.
Revance Therapeutics (Nasdaq: RVNC) will present an ePoster at the 2021 American Academy of Neurology Annual Meeting, showcasing results from the ASPEN-1 Phase 3 trial of DaxibotulinumtoxinA for Injection, targeting cervical dystonia. The trial demonstrated a median treatment effect duration of up to 24 weeks, suggesting a potential 50% reduction in annual treatment frequency. The FDA previously granted orphan drug designation for this treatment, indicating significant developmental support.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced that CEO Mark Foley will participate in fireside chats at two major virtual healthcare conferences. The first is the Cowen 41st Annual Virtual Healthcare Conference on March 3, 2021, followed by the Barclays Global Healthcare Conference on March 9, 2021. Interested parties can listen to the live audio webcast through the Investor Relations section of Revance's website, with a replay available for 30 days post-conference. Revance focuses on innovative aesthetic and therapeutic products, including its neuromodulator, DaxibotulinumtoxinA.
Revance Therapeutics, Inc. (Nasdaq: RVNC) granted 6,601 inducement restricted stock awards (RSAs) to a new employee. The RSAs will vest over four years, with 25% vesting each anniversary, contingent on the employee's continued service. This award was approved by the Compensation Committee of Revance's Board in compliance with NASDAQ Listing Rule 5635(c)(4). Revance specializes in innovative neuromodulator products, notably DaxibotulinumtoxinA for Injection, which is under U.S. regulatory review after a successful Phase 3 program for glabellar lines.
FAQ
What is the current stock price of Revance Therapeutics (RVNC)?
What is the market cap of Revance Therapeutics (RVNC)?
What does Revance Therapeutics, Inc. specialize in?
What is the TransMTS® peptide delivery system?
What are the main products of Revance Therapeutics?
What is RT001?
What are the business segments of Revance Therapeutics?
How does Revance's TransMTS technology benefit its products?
What is the significance of DaxibotulinumtoxinA?
What is the RHA Collection?
What is the HintMD platform?
How does Revance's Product segment contribute to its revenue?
